Market Trends of Europe Ovarian Cancer Diagnostics and Therapeutics Industry
This section covers the major market trends shaping the Europe Ovarian Cancer Diagnostics & Therapeutics Market according to our research experts:
Immunotherapy is Expected to Hold Significant Share of the European Ovarian Cancer Diagnostics and Therapeutics Market During the Forecast Period
Immunotherapy is a type of therapy that uses drugs to suppress or stimulate the immune system to help the body fight infection and ovarian cancer. It relates to a type of biological therapy for ovarian cancer treatment that boosts the body's natural defenses to fight cancer. It may work by stopping or slowing the growth of cancer cells. It will also strengthen the immune system and prevent cancer from spreading to other parts of the body. These therapies are made by the body or in a laboratory to improve or restore immune system function. The increasing product launches for the treatment of ovarian cancer and product development are expected to drive the growth of the market studied during the forecast period.
For instance, the increasing research studies in the region are contributing to the growth of the market segment. For instance, in October 2022, Mendus AB planned for the release of the presentation of the first clinical data from the ongoing ALISON Phase I trial that evaluates the safety and feasibility of its maintenance immunotherapy product candidate DCP-001 in ovarian cancer.
Similarly, in October 2021, Alkermes PLC headquartered in Ireland, initiated ARTISTRY-7, Phase 3, an open-label, randomized trial evaluating the anti-tumor activity and safety of intravenously administered nemvaleukin alfa, in combination with pembrolizumab, in patients with platinum-resistant ovarian cancer.
Hence, owing to the above-mentioned factors, along with the rising burden of ovarian cancer, the market for chemotherapy is expected to grow during the forecast period.
The United Kingdom is Expected to Dominate the European Ovarian Cancer Diagnostics and Therapeutics Market Over the Forecast Period
The United Kingdom is expected to show significant growth during the forecast due to a high number of ovarian cancer cases reported in the country. In addition, there are a large number of clinical trials conducted in the country. According to data published by GLOBOCAN 2020, the incidence of ovarian cancer in the United Kingdom in 2020 was 6,065 cases. Such a high incidence of ovarian cancer in the United States is expected to drive the growth of the studied market in the United Kingdom.
Additionally, the development of ovarian diagnostics in the United Kingdom is expected to contribute to the growth of the market. In May 2022, the Universities of Manchester, Birmingham, and Exeter conducted a study to determine if human epididymis protein 4 (HE4), found in the blood, could help identify ovarian cancer more accurately and save other women from unnecessary and often invasive procedures such as biopsies and physical examinations. Such developments are expected to contribute to the growth of the market during the forecast period in the United Kingdom.
Furthermore, the availability of ovarian cancer therapeutics in the United States is expected to boost the growth of the market. For instance, in January 2021, Zejula, marketed by Tesaro, was available in the United Kingdom as maintenance therapy for advanced ovarian cancer.
Thus, the above-mentioned factors are expected to drive the growth of the market during the forecast period in the United Kingdom.
